Please login to the form below

Not currently logged in
Email:
Password:

Ron Menezes joins Almirall’s Aqua Pharmaceuticals

He joins the US dermatology group as its president and general manager

Amirall's US dermatology company Aqua Pharmaceuticals has appointed Ron Menezes as its new president and general manager.

Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.

Prior to his role at Depomed, Menezes was at Allergan in senior roles including vice president sales and marketing, medical dermatology and he has also held positions at Abbott, Astellas and Pfizer.

Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals.

“Ron’s incorporation and he experience he brings in dermatology represent a clear and undeniable opportunity to further strengthen this organisation.”

Menezes will replace Ted White, who has been president and general manager of Aqua Pharmaceuticals since January 2016.

Sanchiz added: “Almirall continues to consider Aqua as a very important platform in the US market to support existing and new products.”

Aqua Pharmaceuticals was acquired by the Spanish group back in 2013 - a deal that was worth around $400m - to access the US dermatology market.

23rd August 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...